An open, randomised, comparative, multicentre study of the immunogenicity and safety of M-M-R II [measles mumps and rubella virus vaccine] manufactured with recombinant human albumin (rHA) and VARIVAX [varicella zoster virus vaccine live] when administered concomitantly by intramuscular (IM) route or subcutaneous (SC) route at two separate injection sites in healthy subjects 12 to 18 months of age

Trial Profile

An open, randomised, comparative, multicentre study of the immunogenicity and safety of M-M-R II [measles mumps and rubella virus vaccine] manufactured with recombinant human albumin (rHA) and VARIVAX [varicella zoster virus vaccine live] when administered concomitantly by intramuscular (IM) route or subcutaneous (SC) route at two separate injection sites in healthy subjects 12 to 18 months of age

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Measles mumps and rubella virus vaccine (Primary) ; Measles mumps and rubella virus vaccine (Primary) ; Varicella zoster virus vaccine live (Primary) ; Varicella zoster virus vaccine live (Primary)
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 15 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top